Press Releases
July 6, 2023
jCyte Welcomes New Strategic Advisory Board Members, Experts in Inherited Retinal Diseases
July 12, 2022
jCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer
November 15, 2021
jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy
October 19, 2021
jCyte Announces Appointment of John Pollack, MD, FASRS, as Chief Medical Officer
September 9, 2021
jCyte Announces Appointment of Victor Chao as Vice President of CMC Operations
July 6, 2021
jCyte Announces Appointment of Adrian Morris as Chief Development Officer
June 22, 2021
jCyte Announces Appointment of Dr. Adam Walsh as Chief Financial Officer
May 25, 2021
jCyte Announces Appointment of John Sholar as General Counsel
April 22, 2021
jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
June 30,2020
jCyte Inc. Announces Scientific Advisory Board with Distinguished Retinal Physicians
In the News
Foundation Fighting Blindness | February 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
UCI Beall Applied Innovation | November 27, 2023
Is Cell Regeneration a Cure for Blindness?
California Institute for Regenerative Medicine – Annual Report | October 19, 2023
Profile in Progress – New Vision, New Hope (see page 17)
USA TODAY | September 22, 2023
jCyte: Revolutionizing Treatment for Degenerative Retinal Disorders
Ophthalmology Innovation Source – Spotlight on Regenerative Medicine | July 27, 2023
John Pollack, MD, provides an overview of regenerative medicine in ophthalmology.
Adrian Morris presents key learnings from jCyte’s Phase 2b data and the impact to future trial design.
Ophthalmology Times | July 21, 2023
Retinal progenitor cells: Targeting retinitis pigmentosa
Octane Ophthalmology Tech Forum – Innovations of the Future | June 9, 2023
John Pollack, MD, presents key learnings from jCyte’s Phase 2b data and the impact to future trial design.
Foundation Fighting Blindness | April 28, 2023
Eye on the Cure Podcast Episode 45: Henry Klassen, MD, PhD, talks to host Ben Shaberman about jCyte's clinical trial results and future plans for developing its cell-based therapy for retinitis pigmentosa and related retinal conditions.
THE STEM CELLAR | SEPT 2, 2022
How stem cells helped Veronica fight retinitis pigmentosa and regain her vision
BioSpace | May 1, 2021
jCyte Announces Promising Phase IIb Results for Allogeneic Retinal Stem Cell Therapy
Opthalmology Times | Oct 5, 2020
Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases
Financial Times | Sept 14, 2020
Cell therapy opens up new cure horizons
Retinal Physician | Sept 1, 2020
Trial data on gene therapy, proposed Medicare cuts, FDA clearance of an AI diagnostic for DR, and more.
Optical Journal | Aug 13, 2020
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa
The Stem Cellar | July 29, 2020
Encouraging news for treatment targeting retinitis pigmentosa
Eyewire News | July 27, 2020
jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
Endpoints News | July 27, 2020
Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb
Review of Ophthalmology | July 9, 2020
Regenerative Medicine In Ophthalmology
UCI | June 4, 2020
UCI Startup Company jCyte Partners with Santen Pharmaceutical
Orange County Business Journal | May 27, 2020
Biotech jCyte Inks $252M Licensing Deal
Healio | May 14, 2020
Santen to commercialize jCyte’s jCell therapy outside US
The Stem Cellar | May 11, 2020
A Clear Vision for the Future
Global Genes | May 11, 2020
JCyte Licenses Ex-US Rights to Retinitis Pigmentosa Cell Therapy to Santen for $252 Million
Pharmaceutical Business Review | May 11, 2020
JCyte signs ex-US licensing deal with Santen for retinal disease therapy
The Pharma Letter | May 9, 2020
jCyte out-licenses rare vision disorder treatment for $252 million
Biocentury | May 8, 2020
jCyte-Santen deal positions CIRM-funded stem cell therapy for pivotal studies, global access
Bioworld | May 8, 2020
Santen inks $252M license to Jcyte ocular cell therapy
